Loading...
•
Jun 30, 2023
Supernus Q2 2023 Earnings Report
Reported a decrease in total revenues due to decline in Trokendi XR sales, offset by growth in Qelbree and GOCOVRI sales.
Key Takeaways
Supernus Pharmaceuticals reported a decrease in total revenues for Q2 2023, primarily due to the decline in Trokendi XR sales. However, Qelbree and GOCOVRI net product sales experienced growth, with combined sales increasing by 67% compared to the same period last year. The company reiterates its full year 2023 financial guidance.
Qelbree net product sales grew by 179% in the first three months of 2023 compared to the same period in 2022.
GOCOVRI net product sales grew by 17% in the first three months of 2023 compared to the same period in 2022.
Total revenues decreased by 20% in the second quarter of 2023 compared to the same period in 2022.
Operating loss (GAAP) was ($17.6) million for the second quarter of 2023, compared to operating earnings of $11.3 million for the same period in 2022.
Revenue by Segment
Forward Guidance
The company reiterates its prior full year 2023 financial guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...